The first experience of cord blood stem cells application in kidney transplantation: A descriptive study

O.  Voroniak; R.  Zograbian

doi:10.31450/ukrjnd.3(75).2022.05

O. Voroniak SI «Shalimov’s National Institute of Surgery and Transplantation NAMS of Ukraine» https://orcid.org/0000-0001-7188-5596
R. Zograbian SI «Shalimov’s National Institute of Surgery and Transplantation NAMS of Ukraine»

DOI: https://doi.org/10.31450/ukrjnd.3(75).2022.05

Keywords: kidney transplantation, induction immunosuppressive therapy, umbilical cord blood stem cells, chronic renal failure

Abstract

Abstract. Kidney transplantation is recognized as the optimal method of end-stage kidney disease treatment, but chronic renal allograft rejection remains an unresolved issue and leads to transplanted organ function loss. Recent studies show positive effects of stem cell injections in a variety of diseases, including kidney transplantation.

The present study aimed to analyze the first experience of umbilical cord blood stem cells application in living-related kidney transplantation in Shalimov’s National Institute of Surgery and Transplantation, give a preliminary assessment of their effectiveness and safety, evaluate the clinical course and especially the dynamics of laboratory parameters in the recipient’s postoperative period.

Methods. The study group included 6 male, adult recipients of kidney transplants, who performed the first kidney allotransplantation from a living family donor in the Shalimov’s National Institute of Surgery and Transplantology in 2020 – 2021. Before surgery, all patients received intravenous administration of a fraction of nuclear cells from human umbilical cord blood at a dose of 2-3 x 10⁶/kg body weight in combination with standard three-component immunosuppressive therapy. Immune system studies were performed before kidney transplantation, on the first and third days of the postoperative period, at the end of the first and second week, as well as on the first, third, sixth, and twelfth months, following kidney transplantation. Renal graft function was assessed by serum creatinine and glomerular filtration rate. Monitoring of clinical and laboratory parameters of blood and urine, the concentration of calcineurin inhibitors (C0) was carried out regularly three times a week for the first month, twice a month for 2-3 months, and once a month until the end of the year.

Puncture biopsy of the transplanted kidney was performed three months after surgery to diagnose the pathology of the graft, namely the manifestations of acute and chronic rejection, the nature and degree of which were determined according to the Banff classification.

The state of the immune system of the recipients was characterized by indicators of cellular and humoral immunity.

Statistical processing of research results was performed using the statistical package StatSoft (2010) STATISTICA 9.1 for Windows StatSoft Inc, Tusla.

Results. All patients received cord blood stem cells without complications. On the first day after surgery, an average diuresis was 9415 ± 928.1 ml. Normalization of graft function was observed on the second or third day (GFR more than 90 ml/ min/1.73 m²). There were no rejections of grafts and signs of opportunistic infections in the patients during 1 year follow-up period. Morphological studies did not reveal signs of significant pathological changes in transplanted kidneys in patients who received stem cells as induction therapy.

The study of the state of the immune system of recipients in the dynamics, given the insufficient number of patients, requires further research.

Conclusions. The administration of cord blood stem cells to recipients prior to kidney transplantation is safe and promotes rapid recovery of renal allograft function. There were no signs of morphological proven chronic graft rejection, which allows us to predict its long-term functioning in the future. To assess the response of the recipient's immune system to the application of cord blood stem cells requires the accumulation of additional data.

Downloads

Download data is not yet available.

References

Benjamens S, Moers C, Slart RHJA, Pol RA. Kidney Transplantation and Diagnostic Imaging: The Early Days and Future Advancements of Transplant Surgery. Diagnostics (Basel). 2020;11(1):47. doi: 10.3390/diagnostics11010047.

Pinchuk A.V. Induction immunosuppression in kidney transplantation: Thymoglobulin® (a literature review). Transplantologiya. The Russian Journal of Transplantation. 2014;(2):31-43. [In Russian].

Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3.

Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-77. doi: 10.1056/NEJMoa060068.

Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess. 2016;20(62):1-594. doi: 10.3310/hta20620.

Coemans M, Süsal C, Döhler B, Anglicheau D, Giral M, Bestard O, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int. 2018;94(5):964-973. doi: 10.1016/j.kint.2018.05.018.

Justiz Vaillant AA, Mohseni M. Chronic Transplantation Rejection. [Updated 2022 Jul 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from : https://www.ncbi.nlm.nih.gov/books/NBK535435/

Foley RN, Chen SC, Solid CA, Gilbertson DT, Collins AJ. Early mortality in patients starting dialysis appears to go unregistered. Kidney Int. 2014;86(2):392-8. doi: 10.1038/ki.2014.15.

Voroniak O, Zograbian R. The opportunity of stem cells application in kidney transplantation: experimental studies (review). Počki. 2020;9(4):240-248. doi: 10.22141/2307-1257.9.4.2020.218239. [In Ukrainian].

Jeong HJ. Diagnosis of renal transplant rejection: Banff classification and beyond. Kidney Res Clin Pract. 2020;39(1):17-31. doi: 10.23876/j.krcp.20.003.

Duchatsch F, Constantino PB, Herrera NA, Fabrício MF, Tardelli LP, Martuscelli et al. Short-term exposure to dexamethasone promotes autonomic imbalance to the heart before hypertension. J Am Soc Hypertens. 2018;12(8):605-613. doi: 10.1016/j.jash.2018.06.004.

Ilyas M, Colegio OR, Kaplan B, Sharma A. Cutaneous Toxicities From Transplantation-Related Medications. Am J Transplant. 2017;17(11):2782-2789. doi: 10.1111/ajt.14337.

Dominy KM, Willicombe M, Al Johani T, Beckwith H, Goodall D, Brookes P, et al. Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection. Kidney Int Rep. 2018;4(1):148-158. doi: 10.1016/j.ekir.2018.09.005.

Zhao L, Hu C, Han F, Chen D, Cheng J, Wu J, et al. Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis. Stem Cell Res Ther. 2021;12(1):158. doi: 10.1186/s13287-021-02219-7.